Latest news with #LUNAR
Associated Press
29-04-2025
- Science
- Associated Press
Lunar Resources and NASA Achieve Historic Breakthrough in Lunar Oxygen and Metal Extraction from Regolith Simulant
Houston company and NASA demonstrate full scale extraction of resources from simulated lunar soil 'This monumental achievement, 20 years in the making, is a major leap forward for the lunar community.'— Dr. Alex Ignatiev, CTO of LUNAR HOUSTON, TX, UNITED STATES, April 29, 2025 / / -- Lunar Resources (LUNAR), a Houston-based space industrial company pioneering lunar resource extraction technologies, has achieved a groundbreaking milestone in collaboration with NASA's Kennedy Space Center (KSC). In December, LUNAR and NASA successfully demonstrated the extraction of oxygen at a commercial scale from simulated lunar soil (regolith) at KSC's Swamp Works. The demonstration showcased LUNAR's LR-1 resource extraction reactor, an advanced system engineered to electrolytically extract oxygen and metals from lunar soil. Conducted in a simulated lunar vacuum environment within KSC's vacuum chamber, the test lasted over 36 hours, processing 25 kilograms (55 lbs) of simulated lunar soil while producing oxygen. 'This marks the first-ever production of oxygen at full scale from lunar soil simulant in a vacuum environment,' said Dr. Alex Ignatiev, LUNAR's Chief Technology Officer. 'This monumental achievement, 20 years in the making, is a major leap forward for the lunar community.' The LR-1 system employs molten regolith electrolysis (MRE), a high-temperature electrolytic process that uses only electric current to separate oxygen and metals from lunar soil. Alongside oxygen extraction, the demonstration produced valuable metals such as iron and silicon, further expanding the potential for lunar resource utilization. The project was jointly funded by NASA's Space Technology Mission Directorate (STMD) Game Changing Development (GCD) program and LUNAR's internal research and development initiatives. Resource extraction from lunar soil is a critical component for achieving lunar sustainability under NASA's Artemis Program. The LR-1 demonstration is the first instance of full-scale extraction of both oxygen and metals from simulated lunar soil, paving the way for a dependable and cost-effective supply of raw materials on the Moon's surface. About Lunar Resources Based in Houston, Texas, Lunar Resources, Inc. is space industrial company developing off-earth industrial technologies that advance the utilization of the resources of space for commercial, scientific, and strategic applications. For more information, please contact [email protected] or visit Elliot Carol Lunar Resources, Inc. [email protected] Visit us on social media: X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Business Wire
22-04-2025
- Business
- Business Wire
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the 'Company', 'Arcturus', Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025. Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit In addition, please connect with us on Twitter and LinkedIn.
